Dilaforette is currently developing a new drug for treatment of severe malaria patients. There are 250 million malaria cases per year resulting in close to one million deaths, mostly children. Despite antimalarial treatment, 10 percent or more of the patients with severe malaria die. Low anticoagulant heparin (LAH) is a potential new adjunctive treatment of severe malaria that acts by preventing and reversing the infected cells’ ability to block blood vessels.
Dilaforette was founded by leading scientists in malaria from Karolinska Institute and leading experts in the field of heparin and drug development from Uppsala University and the Swedish pharmaceutical industry together with Karolinska Innovation AB.